Legal Insights Archive

5 Red Flags In Pharmaceutical Settlements

Big Data, Price Intelligence and Antitrust

Clones Not Patent-Eligible?

Three Reasons PTAB Litigation Costs More than We Thought

Claims Without Merit Are the Problem, Not Trolls

Carrying Your Umbrella When Navigating the Cloud

Matching Colors And Policies: Insurers May Be On The Hook

No Surprises at Trial: Authentication, Best Evidence Rule and Admissibility of Expert Testimony

U.S. Patent Trial and Appeal Board Decisions: Secondary Considerations of Non-Obviousness—What Is the Likelihood of Getting Discovery?

The FDA’s “Natural” Reluctance: What it Means for Class Action Lawsuits

Personalized Medicine and Patent Eligibility under 35 U.S.C. § 101

Big Data, Social Media, and IP: How to Make “Likes,” “Tweets,” and “+1’s” Your Trade Secrets

Screen Writing For Screen Reading

Update: Stryker Rejuvenate and ABGII Lawsuits Progress in New Jersey State Court

Eli Lilly and Company v. Teva Parenteral Medicines, Inc.

Generic Launches

ANDA Litigation Settlements

Senju Pharmas. Co., Ltd. v. Apotex Inc. (Fed Cir)

Allergan, Inc. v. Sandoz Inc.

The Medicines Co. v. Hospira, Inc.

Apotex, Inc. v. Daiichi Sankyo Co.

Shire Dev. LLC v. Watson Pharms., Inc.

Pfizer Inc. et. al v. Teva Pharmaceuticals USA, Inc. et al. (Fed Cir)

ANDA Approvals

Warner Chilcott Co., LLC v. Teva Pharms. USA, Inc.

Classen Immunotherapies, Inc. v. Shionogi, Inc.

Par Pharms., Inc. v. TWi Pharms., Inc.

Endo Pharms. Inc. v. Actavis, Inc. (Fed Cir)

G.D. Searle LLC v. Lupin Pharms, Inc.

Alcon Research Ltd. v. Barr Labs., Inc.

New ANDA Cases

Purdue Pharma L.P. v. Teva Pharms. USA, Inc.

In re Lamictal Direct Purchaser Antitrust Litigation

Endo Pharmas. Inc. v. Mylan Pharmas. Inc.

Takeda Pharma. Co. Ltd. v. Zydus Pharmas. USA, Inc. (Fed Cir)

GlaxoSmithKline LLC v. Banner Pharmacaps, Inc. (Fed Cir)

Warner Chilcott Co. LLC v. Lupin Ltd.

Calif. Odor Case Stinks For Businesses With CGL Policies

Natural-Labeling Litigation: Preparing for the Next Five Years

How to Manage Mobile Big Data Legal Risks

Canadian Antitrust Class Actions — A Business Opportunity

Finding the Line Separating Infringement and Exempt Uses: Enforcing Biotechnology Patents in View of 35 U.S.C. § 271(e)(1)

The Eight Corners Rule: Uncertainty On Duty To Defend

Patent Owners Beware, Your Patent has a 15 Percent Chance (Or Less) of Surviving the PTAB

Maintaining the Attorney-Client and Work-Product Privileges in an Internal Investigation

Inter Partes Review: Is It Working to Make the Patent System Better?

Let's Chat About the Legal Risks of Instant Messaging

Staying Alive Redux

Central District of California Holds That Criminal Amnesty Recipients not Entitled to ACPERA Benefits in Parallel Civil Action Where Cooperation in Civil Action Untimely

Harnessing Big Data to Turn Consumer Social Media into Trade Secrets by Tom Mahlum